Inspire Q4 Prel. Revenue Rises 12%, Sees Double-Digit Growth In 2026; Names Matt Osberg CFO

Inspire Medical reported preliminary Q4 revenue of $268.9M–$269.1M (≈+12% YoY) and FY2025 revenue of $911.8M–$912.0M (≈+14% YoY), and guided fiscal 2026 revenue of $1.003B–$1.013B, implying 10%–11% growth. The company also appointed Matt Osberg as EVP and CFO; shares rose over 2% in pre-market trading. The guidance crossing roughly $1.0B and continued double‑digit growth signals positive operational momentum that is likely to affect near-term valuations and investor models.

Analysis

Market structure: Inspire (INSP) is the clear beneficiary—guidance for FY26 >$1.00B (10–11% growth) plus a new CFO improves confidence in execution and should support pricing power for the implantable hypoglossal therapy vs. CPAP incumbents. Hospitals, ENT surgeons and device-component suppliers see higher procedure volumes and revenue visibility; CPAP OEMs (e.g., RMD, PHG) face incremental share loss in patients migrating to device therapy. On cross-assets, expect modest equity outperformance for medtech growth names, marginal tightening in credit spreads for investment-grade peers, and a short-term dampening of options implied volatility as upside becomes priced in.

Risk assessment: Tail risks include an FDA label change or a major reimbursement reversal by CMS (low probability, high impact) and operational risks from supply-chain or procedural-capacity constraints that would depress adoption. Near-term (days-weeks) price sensitivity is to guidance cadence and any revision; medium-term (3–12 months) hinges on procedure growth and payer coverage; long-term (>12 months) depends on durable reimbursement and international expansion. Hidden dependencies: reimbursement timelines lag revenue and a CFO focused on margin optimization could reallocate R&D vs. sales, altering growth trajectory; catalysts to watch: quarterly procedure metrics, CMS notices, and competitor clinical data.

Trade implications: Direct tactic is constructive on INSP with calibrated exposure: theorem is upside to ~25–35% within 6–12 months if FY26 guide holds and adoption continues; downside truncation if CMS/clinical news turns negative. Use options to express this—bull call spreads to limit capital at risk while capturing upside—and consider a relative-value pair (long INSP, short ResMed RMD or long-medtech ETF hedge) to isolate device-adoption upside vs. broader sleep-Rx market weakness. Time entries into pullbacks below $95 and trim into strength above $125.

Contrarian angles: Market may under-price the margin uplift from scale—if gross margins expand 300–500 bps as unit volume grows, EPS leverage could outpace revenue, making INSP a stealth earnings compounder. Conversely, consensus may be underestimating payer pushback; a single adverse CMS decision would compress multiple quarters of expected upside. Historical parallels: durable device adoption curves (e.g., early cardiac devices) show front-loaded regulatory/coverage noise then sustained uptake; mispricings will appear around CMS/clinical milestones where volatility should be sellable rather than buyable.

Key Decisions for Investors

• Establish a 2–3% portfolio weight long in INSP (ticker INSP) on strength of FY26 guide; tranche buys: 50% now near $98, 50% on pullback to $88–95. Target 6–12 month price objective +25–35% (~$123–$133). Set stop-loss at -12% below entry to limit downside.
• Use options to define risk: buy a 9–12 month bull-call spread (e.g., long INSP 12-month 100C, short 12-month 140C) sized to risk no more than 1% of portfolio value. This captures upside if adoption persists while capping max loss.
• Implement a pair trade: long INSP vs short ResMed (RMD) 1:0.6 (dollar neutral) for 3–6 months to isolate device-adoption upside; unwind if INSP procedural growth prints <5% sequentially or if RMD reports >5% share gain in device conversions.
• Risk triggers to act: reduce/exit INSP if FY26 guide midpoint falls below $1.000B, or if next two quarterly procedure growth prints are <5% QoQ. Monitor CMS reimbursement notices and any major FDA advisory within the next 90 days and reprice positions around those events.